Mendus AB (CHIX:IMMUS) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IMMUS Mendus AB CHIX:IMMUS
30 GF Score
Price kr32.70
! 2 Warning Signs
View Full Analysis

What is Mendus AB Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

CHIX:IMMUS
30GF Score
Mendus AB CHIX:IMMUS
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Business Description

Other Exchanges IMMU:Sweden1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
30GF Score

Get the complete analysis for CHIX:IMMUS

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr32.70
Price